Chronic Pulmonary Aspergillosis, Progressing on Azole Therapy in a Resistance Hot Spot
A single patient, fourteen months into therapy that had been working. The disagreement is whether a worsening cavity means the organism outran the drug, or the drug never reached it in the first place.
R.H., a 67-year-old woman, spent forty years running a small florist's shop and still keeps a raised garden bed at home, tending it most mornings despite the fibrotic lung damage left behind by tuberculosis she survived in her thirties. She has been on itraconazole for fourteen months for chronic pulmonary aspergillosis colonizing that old scarred cavity, and until three weeks ago her disease had been stable — modest hemoptysis, unchanged imaging, a slowly falling Aspergillus IgG titer that suggested the drug was doing its job. Her eGFR has sat around 48 for years, which is not the number that decides how sick she is but is the number that decides what she can be treated with: it converts a switch to amphotericin B from a straightforward escalation into a cost paid up front, before anyone knows whether it buys anything. That trend has reversed: her hemoptysis has worsened over the past ten days, and a repeat CT shows cavity enlargement rather than the stability her last three scans had shown.
She lives in a region with documented environmental azole resistance in Aspergillus fumigatus, driven by agricultural fungicide exposure — the same TR34/L98H mutation in the fungal cyp51A gene that Snelders and colleagues traced to fungicide-treated soil rather than to patients' own prior azole exposure, in the work that established environmental resistance as a route into azole-naive lungs — soil of the kind she has turned over by hand for decades. Regional isolate surveys here have put resistance prevalence in the range the ESCMID/ERS chronic pulmonary aspergillosis guideline, written under Denning, cites as a threshold for empirically broadening therapy rather than waiting on culture-based susceptibility, which can take one to two weeks a patient with worsening hemoptysis may not comfortably have. But progression on azole therapy in chronic pulmonary aspergillosis has an older, more common explanation than resistance: the drug reaching a fibrotic, poorly vascularized cavity in concentrations lower than a peripheral serum level would suggest, independent of whether the organism itself remains susceptible. Her renal function is already marginal from decades of disease, which makes the amphotericin B alternative to itraconazole a real cost, not a free substitution, if the actual answer to why she's worse turns out to be one a level check could have answered first, and no one has actually drawn that level since her last stable scan more than six months ago.
In clinic, reading a cavity that stopped shrinking
Our regional surveillance has TR34/L98H prevalence at a level the ESCMID/ERS chronic pulmonary aspergillosis guideline already cites as a threshold for broadening therapy empirically rather than waiting on culture — and Snelders showed years ago that this genotype arrives from the environment, not from prior azole exposure, so her fourteen clean months don't protect her from it. Worsening hemoptysis through fourteen months of an azole is a treatment-failure signal on its own — I want liposomal amphotericin B started today, not after two more weeks of a cavity that's already enlarging.
You're right that hemoptysis progressing on therapy is a red flag regardless of mechanism — I'm not disputing that part. But most progression in chronic pulmonary aspergillosis is a penetration problem, not a resistance problem: a fibrotic, poorly vascularized cavity like hers can run drug concentrations well under what her serum level implies, with the organism still fully susceptible. Her eGFR is already 48. Switching everyone at a population resistance rate to amphotericin B treats a probability as a certainty in one specific patient with real renal cost on the table.
The surveillance number describes environmental isolates in the region generally — it isn't a susceptibility result on her own organism, and we have a faster way to find out something real before committing to that toxicity.
Her itraconazole trough hasn't been checked in over six months, and a level result is back same-day — faster than either the regional-threshold argument or the culture we've already sent. If her level is subtherapeutic, this is a dosing problem hiding behind a resistance question, fixable without amphotericin B at all. If it's therapeutic, that changes the weight of both positions above. I'd draw the level today, hold the amphotericin B decision until it results, and keep it as the explicit next step if the level comes back adequate.
Agreed: itraconazole level drawn same-day, culture/susceptibility already pending, and a 48-hour follow-up call scheduled to review whichever result returns first rather than waiting for both.
Not agreed: whether this delay is itself already too long. The ID physician accepted the level check but stated for the record that he would have started amphotericin B today in a patient with faster-progressing hemoptysis, and considers her clinical trajectory close enough to that line that the group should revisit the threshold at the next visit rather than treat 48 hours as automatically safe.